Article citationsMore>>
Sue, S., Kuwashima, H., Iwata, Y., Oka, H., Arima, I., Fukuchi, T., Sanga, K., Inokuchi, Y., Ishii, Y., Kanno, M., Terada, M., Amano, H., Naito, M., Iwase, S., Okazaki, H., Komatsu, K., Kokawa, A., Kawana, I., Morimoto, M., Saito, T., Kunishi, Y., Ikeda, A., Takahashi, D., Miwa, H., Sasaki, T., Tamura, T., Kondo, M., Shibata, W. and Maeda, S. (2017) The Superiority of Vonoprazan-Based First-Line Triple Therapy with Clarithromycin: A Prospective Multi-Center Cohort Study on Helicobacter pylori Eradication. Internal Medicine, 56, 1277-1285.
https://doi.org/10.2169/internalmedicine.56.7833
has been cited by the following article:
-
TITLE:
Efficacy and Tolerability of Second-Line Metronidazole Triple Therapy Using Vonoprazan for Helicobacter pylori Eradication in Japan—Comparative Study: Vonoprazan vs. Proton Pump Inhibitors
AUTHORS:
Masahiko Ohtaka, Mika Miura, Mitsuhiko Hanawa, Yuichi Hirose, Atsuko Kitahashi, Naoki Imamura, Ikko Watanabe, Kazuhiko Takaso, Naoki Shimura, Yoshioki Yoda, Ichiro Takayama, Mitsuharu Fukasawa, Nobuyuki Enomoto
KEYWORDS:
Vonoprazan, Metronidazole, Proton Pump Inhibitor, Second-Line Eradication, Helicobacter pylori
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.8 No.1,
January
31,
2018
ABSTRACT: Aim: To investigate the efficacy and tolerability of second-line metronidazole triple therapy with vonoprazan (VPZ) for Helicobacter pylori (H. pylori). Methods: We retrospectively reviewed medical records of patients who experienced clarithromycin triple therapy failure and were treated with second-line (20 mg VPZ (n = 274)/30 mg lansoprazole (n = 323) or 10 mg rabeprazole (n = 141) twice daily, 750 mg amoxicillin twice daily, 250 mg metronidazole twice daily for 7 days) eradication therapies. Successful eradication rates were compared between two groups: those receiving VPZ and those receiving a proton pump inhibitor (PPI). Adverse events were also investigated. Results: Successful second-line eradication rates according to ITT analysis and PP analysis, respectively, were 79.9% and 92.4% for VPZ therapy and 83.6% and 93.3% for PPI therapy. There were no significant differences between treatment groups. The eradication rates in those who had received first-line VPZ therapy previously according to ITT and PP analysis were 75.2% and 88.1%, respectively; in contrast, values were 82.5% and 95.4%, respectively, for those who had received first-line PPI therapy previously. In second-line therapy, the overall adverse event rate for VPZ therapy was the same as for PPI therapy. Conclusions: The efficacy and tolerability of metronidazole-containing second-line triple therapy with VPZ or a PPI were equivalent.
Related Articles:
-
Andrew Beckwith
-
R. Douglas Martin, Shengyu Zhang
-
Du Thanh Hang, Than Thi Thanh Tra, Le Minh Tuan, Geoffrey Peter Savage
-
Boukaka Kala Rel Gerald, Kinata Bambino Sinclair Brice, Ekouele Mbaki Hughes Brieux, Bingui Outman Pascal Diogène, Boukassa Léon, Moukouengo Nee Kaya Fleur Patricia, Mabiala Babela Jean Robert
-
Pascal Diogène Bingui Outman, Nelly Sandrine Guembo Pandzou, Rolyne Vanissia Madzou Nganie, Verlem Bomelefa-Bomel, Benoite Diatewa, Kadidja Grace Nkounkou Milandou, Jean Brice Mouendenguia, Luopou Lamah, Audrey Niangui-Bakala, Dorthéa Banga Massalat, Rel Gérald Boukaka Kala, Jean Robert Mabiala Babela